ArticleCytotherapy2014
Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System.
Article in Cytotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 153 citations in OpenAlex.
- Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2025Trial
- Mesenchymal Stromal Cell Rejuvenation Strategies to Enhance Clinical Translation in Cell Therapy.Aging cell · 2026Review
- Mesenchymal Stromal Cells Improve Postoperative Cardiac Dysmaturation in a Juvenile Porcine Model.Journal of the American Heart Association · 2026Article
- Therapeutic applications of mesenchymal stem cell-derived extracellular vesicles in pain management: A narrative review of emerging evidence and future directions.World journal of stem cells · 2026Review
- Therapeutic Potential of Extracellular Vesicles: From Biogenesis, Isolation and Molecular Characterization to Addressing Translational Gaps and Regulatory Barriers.International journal of molecular sciences · 2026Review
- Mesenchymal Stromal Cells Mitigate Prolonged Cardiopulmonary Bypass-Induced Neuroinflammation.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- The manufacture of AAV for gene therapy applications using a closed, semi-automated hollow-fiber bioreactor.Molecular therapy. Methods & clinical development · 2025Article
- From bench to bedside: the research status and application opportunity of extracellular vesicles and their engineering strategies in the treatment of skin defects.Journal of nanobiotechnology · 2025Review
- Article
- Automated Manufacturing Processes and Platforms for Large-scale Production of Clinical-grade Mesenchymal Stem/ Stromal Cells.Stem cell reviews and reports · 2025Review
- Integration of an automated cell culture analyzer with a closed-system hollow-fiber bioreactor for online metabolite detection and cell monitoring.Journal of biological methods · 2025Article
- Comparative analysis of cryopreserved adipose stem cells expanded in hollow fiber bioreactor versus conventional tissue culture flasks.Scientific reports · 2024Article
- Article
- Engineering extracellular vesicles for ROS scavenging and tissue regeneration.Nano convergence · 2024Review
- Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy.Cells · 2024Review
- Large-scale bioreactor production of extracellular vesicles from mesenchymal stromal cells for treatment of acute radiation syndrome.Stem cell research & therapy · 2024Article
- Hollow fiber bioreactor allows sustained production of immortalized mesenchymal stromal cell-derived extracellular vesicles.Extracellular vesicles and circulating nucleic acids · 2024Article
- Dose Effect of Mesenchymal Stromal Cell Delivery Through Cardiopulmonary Bypass.The Annals of thoracic surgery · 2023Article
- Mesenchymal Stromal Cell Delivery Via Cardiopulmonary Bypass Provides Neuroprotection in a Juvenile Porcine Model.JACC. Basic to translational science · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedErratum.2014 · Cabreira-Harrison, Marie da Graca [corrected to Cabreira-Hansen, Maria da Graca]
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThe use of bone marrow-derived mesenchymal stromal cells (MSCs) as a cellular therapy for various diseases, such as graft-versus-host disease, diabetes, ischemic cardiomyopathy and Crohn's disease, has produced promising results in early-phase clinical trials. However, for widespread application and use in later phase studies, manufacture of these cells must be cost-effective, safe and reproducible. Current methods of manufacturing in flasks or cell factories are labor-intensive, involve a large number of open procedures and require prolonged culture times.
methodsWe evaluated the Quantum Cell Expansion System for the expansion of large numbers of MSCs from unprocessed bone marrow in a functionally closed system and compared the results with a flask-based method currently in clinical trials.
resultsAfter only two passages, we were able to expand a mean of 6.6 × 10(8) MSCs from 25 mL of bone marrow reproducibly. The mean expansion time was 21 days, and cells obtained were able to differentiate into all three lineages: chondrocytes, osteoblasts and adipocytes. The Quantum was able to generate the target cell number of 2.0 × 10(8) cells in an average of 9 fewer days and in half the number of passages required during flask-based expansion. We estimated that the Quantum would involve 133 open procedures versus 54,400 in flasks when manufacturing for a clinical trial. Quantum-expanded MSCs infused into an ischemic stroke rat model were therapeutically active.
conclusionsThe Quantum is a novel method of generating high numbers of MSCs in less time and at lower passages when compared with flasks. In the Quantum, the risk of contamination is substantially reduced because of the substantial decrease in open procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.